South San Francisco Newswire

South San Francisco Newswire

Comprehensive Real-Time News Feed for South San Francisco, CA.

Results 1 - 20 of 44 for "u:pr-inside.com" in South San Francisco, CA

  1. Nodality, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile - New Market ReportRead the original story

    Monday Jul 20 | PR-inside.com

    Nodality, Inc. is a biotechnology company. The company discovers and develops personal diagnostics characterizing cell signaling pathways in defined cellular sub-populations of malignant and normal cells from individual patients.

    Comment?

  2. Trellis Bioscience, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances ProfileRead the original story

    Sunday Jul 12 | PR-inside.com

    Trellis Bioscience, Inc. is a biotechnology company. The company discovers and develops novel human antibody therapeutics for the treatment of infectious diseases and cancer indications.

    Comment?

  3. Monogram Biosciences, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances ProfileRead the original story

    Sunday Jul 12 | PR-inside.com

    Recently published research from GlobalData, "Monogram Biosciences, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile", is now available at Fast Market Research Monogram Biosciences, Inc. is a life sciences company. It develops and commercializes assays for clinical trials.

    Comment?

  4. New Report Available: Fluidigm Corporation (FLDM) - Medical Equipment - Deals and Alliances ProfileRead the original story

    Tuesday Jul 7 | PR-inside.com

    Fluidigm Corporation is a biotechnology company. The company manufactures and markets microfluidic-based chips and instrumentation for biological research.

    Comment?

  5. Just Published: "Portola Pharmaceuticals, Inc. (PTLA) -...Read the original story

    Jun 28, 2015 | PR-inside.com

    Portola Pharmaceuticals, Inc. is a biopharmaceutical company. It undertakes the discovery and development of therapeutics for the treatment of cardiovascular, inflammation, and oncology indications.

    Comment?

  6. Hyperion Therapeutics, Inc. (HPTX) - Pharmaceuticals & Healthcare -...Read the original story

    Jun 28, 2015 | PR-inside.com

    It develops and commercializes novel drugs for the treatment of orphan diseases and hepatology disorders. Ravicti, the company's first approved product is indicated for use as a nitrogen-binding agent in adult and pediatric patients aged above two years suffering with urea cycle disorders and those who cannot be treated by dietary protein restriction and amino acid supplementation alone.

    Comment?

  7. New Market Report: Portola Pharmaceuticals, Inc. (PTLA) - Financial...Read the original story

    Jun 22, 2015 | PR-inside.com

    Portola Pharmaceuticals, Inc. is a biopharmaceutical company. It undertakes the discovery and development of therapeutics for the treatment of cardiovascular, inflammation, and oncology indications.

    Comment?

  8. Theravance, Inc. (THRX) - Financial and Strategic SWOT Analysis Review - New Market Research ReportRead the original story

    Jun 22, 2015 | PR-inside.com

    The company discovers, develops and commercializes small molecule medicines. Its products include relvar and breo ellipta, and anoro ellipta.

    Comment?

  9. Newly released market study: Titan Pharmaceuticals, Inc. (TTNP) -...Read the original story

    Jun 15, 2015 | PR-inside.com

    The company develops therapeutics for the treatment of central nervous system disorders. Its products include probuphine used for the treatment of opioid addiction, iloperidone used for the treatment of schizophrenia and related psychotic disorders.

    Comment?

  10. New Market Report: Exelixis, Inc. (EXEL) - Financial and Strategic SWOT Analysis ReviewRead the original story

    Jun 15, 2015 | PR-inside.com

    Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats.

    Comment?

  11. New Market Report: Exelixis, Inc. (EXEL) - Pharmaceuticals & Healthcare - Deals and Alliances ProfileRead the original story

    May 26, 2015 | PR-inside.com

    It focuses on the development of pharmaceutical products for treatment of cancer and other life threatening diseases. The company has two advanced product candidates: Cometriq , a inhibitor of multiple receptor tyrosine kinases; and Cobimetinib , a potent, highly selective inhibitor of MEK.

    Comment?

  12. Cytokinetics to Hold Annual Meeting of StockholdersRead the original story

    May 13, 2015 | PR-inside.com

    SOUTH SAN FRANCISCO, Calif., May 13, 2015 -- Cytokinetics, Incorporated announced today that its Annual Meeting of Stockholders will be held on Wednesday, May 20, 2015 at 10:30 AM Pacific Time at the Embassy Suites Hotel, located at 250 Gateway Boulevard in South San Francisco, CA. Robert I. Blum, President and Chief Executive Officer, is scheduled to present an overview of Cytokinetics' performance.

    Comment?

  13. Solazyme, Inc. (SZYM) - Alternative Energy - Deals and Alliances Profile - New Market Research ReportRead the original story

    May 8, 2015 | PR-inside.com

    It develops wide range renewable oils, and powerhouse ingredients that find applications in nutrition, skin and personal care, sustainable fuels, and other industrial markets. Its proprietary technology transforms a range of plant-based sugars into high-value triglyceride oils, and other bi-products.

    Comment?

  14. New Report Available: Amgen Inc. (AMGN) - Financial and Strategic SWOT Analysis ReviewRead the original story

    May 5, 2015 | PR-inside.com

    Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats.

    Comment?

  15. Cytokinetics to Announce First Quarter Results on April 30, 2015Read the original story

    Apr 16, 2015 | PR-inside.com

    South San Francisco, CA., April 16, 2015, - Cytokinetics, Incorporated announced today that it is scheduled to report first quarter results on Thursday, April 30, 2015 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company's outlook for the future.

    Comment?

  16. New market study, "Nodality, Inc. - Medical Equipment - Deals and...Read the original story

    Apr 16, 2015 | PR-inside.com

    The company discovers and develops personal diagnostics characterizing cell signaling pathways in defined cellular sub-populations of malignant and normal cells from individual patients. It develops molecular diagnostics to improve clinical decision-making in cancer and autoimmune diseases, with the products targeting treatment management in hematological malignancies.

    Comment?

  17. Cytokinetics to Present at the 14th Annual Needham Healthcare ConferenceRead the original story

    Apr 8, 2015 | PR-inside.com

    South San Francisco, CA, April 8, 2015 - Cytokinetics, Incorporated announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the 14 Annual Needham Healthcare Conference on Wednesday, April 15, 2015 at 11:20 AM at the Westin New York Grand Central in New York, NY. Interested parties may access the live audio of this presentation by visiting the Investor Relations section of the Cytokinetics website at www.cytokinetics.com.

    Comment?

  18. Cytokinetics Announces Publication of Results from Phase II Trial of...Read the original story

    Mar 25, 2015 | PR-inside.com

    Data from Evidence of Effect Trial Provide Support for Novel Mechanism of Action in Neuromuscular Diseases South San Francisco, CA, March 25, 2015 - Cytokinetics, Incorporated announced the publication of a manuscript relating to its fast skeletal muscle troponin activator tirasemtiv in the journal Neurotherapeutics. This publication summarizes results from a Phase IIa "Evidence of Effect" or hypothesis-generating clinical trial which evaluated tirasemtiv in patients with generalized myasthenia gravis .

    Comment?

  19. New Report Available: MPM Capital, L.P. - Medical Equipment - Investment ProfileRead the original story

    Mar 17, 2015 | PR-inside.com

    It focuses investments into biotechnology, medical technology, specialty pharma and related companies that provide medical products and services to the healthcare industry. The firm is structured to invest in healthcare innovation globally, irrespective of geography, stage of development and therapeutic area.

    Comment?

  20. Report Published: "diaDexus, Inc. (DDXS) - Financial and Strategic SWOT Analysis Review"Read the original story

    Mar 15, 2015 | PR-inside.com

    The company develops and commercializes in-vitro diagnostic products for the treatment of cardiovascular disease. Its product includes The PLAC Test.

    Comment?

South San Francisco Job Listings
View or post South San Francisco job listings on Topix.
South San Francisco Real Estate
News, listings, and foreclosures in South San Francisco from Topix.
South San Francisco Mortgages
Find mortgage rates in South San Francisco on Topix.